|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.1120 - 0.1400|
|52 Week Range||0.0800 - 0.4960|
|Beta (5Y Monthly)||3.87|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.47|
AB101 was administered subcutaneously in three ascending dosing cohorts in patients with type 1 diabetes, which resulted in slow onset and sustained insulin levels and activity for more than seven days. Consequently, the Company believes that additional formulation development is required before advancing the program further in the clinic. This single ascending dose study, AB101-01, was designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AB101, in subjects with type 1 diabetes who were on background continuous, subcutaneous insulin infusion.
REDWOOD CITY, Calif., Dec. 02, 2019 -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2020 Biotech Showcase.
Rezolute, Inc. (“Rezolute” or the “Company”) (RZLT), a biopharmaceutical company specializing in the development of innovative drug therapies for patients with metabolic diseases, announced today the appointment of Gil Labrucherie to its Board of Directors (“Board”) where he will serve as Chairman of the Audit Committee. Mr. Labrucherie is currently the Chief Operating Officer and Chief Financial Officer of Nektar Therapeutics.
REDWOOD CITY, Calif., Oct. 11, 2019 -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2019 BIO Investor Forum.
REDWOOD CITY, Calif., Aug. 05, 2019 -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2019 Canaccord Genuity.
Rezolute, Inc. (“Rezolute”) (RZLT), a clinical stage biopharmaceutical company specializing in the development of transformative therapies targeting metabolic and orphan diseases, announced today that Handok, Inc. (“Handok”) and Genexine, Inc. (“Genexine”), exercised their combined full $20 million option to purchase shares of Rezolute common stock, increasing their combined aggregate investment in Rezolute to $45 million. Each share of common stock was priced at $0.29 in this offering. “We are very appreciative of the continued support of Genexine and Handok.
NEW YORK , April 18, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...